Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Cancer Cell. 2023 Sep 11;41(9):1545-1547. doi: 10.1016/j.ccell.2023.08.003.
In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials. Although 8.9%-24.4% of patients demonstrate a ≥30% reduction in target lesions, conversely 11%-18% of patients had a ≥20% increase. The benefits of treatment beyond progression must be carefully weighed against physical and financial toxicities.
在本期《癌细胞》中，Topp 等人分析了 6 项试验中 799 例经 RECIST 1.1 评估疾病进展后接受帕博利珠单抗治疗的患者数据。尽管有 8.9%-24.4%的患者靶病灶缩小≥30%，但相反的是，有 11%-18%的患者靶病灶增大≥20%。疾病进展后治疗的获益必须仔细权衡与身体和经济毒性相关的问题。
